Bryan Garnier successfully leads €12 million IPO for Ipsogen
Share the transaction
First healthcare company to list on NYSE Euronext in 2008
PARIS – June 10, 2008 – Bryan, Garnier & Co (“Bryan Garnier”), the independent pan-European investment bank focused on growth companies, today announces the successful closing of a €12 million initial public offering in the form of ordinary shares for Ipsogen (Alternext: ALIPS). Bryan Garnier was the sole lead manager and the sole bookrunner for this transaction.
This is the year’s first Healthcare IPO transaction on NYSE Euronext and consists of a capital increase with no secondary shares. The offering generated strong interest from institutional funds across Europe as well as specialist Healthcare investors. As the demand exceeded the offer, the extension clause and the over-allotment option were fully exercised.
This latest operation is the fifth healthcare related public offering that Bryan Garnier has led over the past twelve months, following four successful placements for Transgene, BioAlliance Pharma, Arkimedica and Medicrea.
Commenting on the transaction, Catherine Trividic, Head of Bryan Garnier’s Healthcare practice said, “The strong investor interest in this latest listing shows that current market conditions don’t have to be an obstacle. The success of this IPO is due to a combination of the company’s outstanding profile and strong management team, the attractive offering and Bryan Garnier’s committed involvement in the operation. Ipsogen is certainly well positioned now to emerge as one of the few leading global players in the booming Molecular Diagnostic field.”
Ipsogen intends to use the funds raised to expand its commercial presence, attain key regulatory milestones and in-license new technologies and relevant biomarkers for blood and breast cancers, its two areas of expertise.
Vincent Fert, CEO of Ipsogen stated: “We are delighted with the success of the capital increase and the listing on Alternext. Bryan Garnier’s industry expertise and level of commitment have been critical to the success of this IPO in the current context of capital market instability. Highly experienced senior bankers and partners of the firm were involved at each stage of the process, and the breadth of their institutional investor relationships in Europe contributed to this successful listing. We are now looking forward to continuing Ipsogen’s rapid growth and maximising value for our shareholders.”
Virginie Lazès, Head of the Corporate Finance said, “This successful transaction demonstrates our close relationships with international investors and the ability of our experienced investment bankers to provide industry-specific advice and deliver solutions to our clients. This operation confirms our position as a leading European investment bank in Healthcare. ”
Virginie Lazès, who recently joined Bryan Garnier as Partner and Head of the Corporate Finance team, will further bolster Bryan Garnier’s industry expertise and international exposure with her proven management skills and her extensive experience in arranging complex financial and trade deals with fast-growing companies.
For more information, please contact:
Kay Larsen / Kerstin Voelkel : Penrose Financial + 44 (0)20 7786 4888
Stanislas Piot, Ipsogen + 33 (0)4 91 29 30 90
About Ipsogen
IPSOGEN is a cancer profiler that develops and markets molecular diagnostic assays designed to map diseases and guide clinicians and patients decisions along the complex therapeutic path.
With more than 60 products already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, IPSOGEN is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that has been inaccessible until now. IPSOGEN is also a partner of choice for biopharmaceutical companies committed to revolutionary companion diagnostics.
Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the US, IPSOGEN is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionnals and society in general.
IPSOGEN employed 40 people as of April 30, 2008. Its headquarters are located in Marseille, France.
The company also has a subsidiary, IPSOGEN Inc., in New Haven, Connecticut, USA.